/ONC.L
ONC.L Stock - Oncimmune Holdings plc
Healthcare|BiotechnologyLSE
$1.14-4.20%
$0.05 (-4.20%) • Mar 14
44
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.48
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ONC.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.13 – $1.15
TARGET (TP)$1.31
STOP LOSS$1.05
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.81
52W High$31.00
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $2.74M | $1.15M | $3.86M | $3.72M | $509,000 |
| Gross Profit | $1.23M | $792,000 | $1.46M | $2.86M | $-28,000 |
| Gross Margin | 44.9% | 68.8% | 37.8% | 76.8% | -5.5% |
| Operating Income | $-3,226,000 | $-4,242,000 | $-8,586,000 | $-5,145,000 | $-9,268,000 |
| Net Income | $-3,628,000 | $4.10M | $-9,512,000 | $-4,628,000 | $-8,459,000 |
| Net Margin | -132.5% | 356.3% | -246.5% | -124.3% | -1661.9% |
| EPS | $-0.05 | $0.06 | $-0.15 | $-0.07 | $-0.13 |
Company Overview
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ONC.LBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.03
Q1 2025
EPS Surprise History
Q4 20
No data
Q1 21
No data
Q4 21
No data
Q1 22
No data
Q2 23
No data
Q3 23
No data
Q2 24
No data
Q1 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | May 19, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | — | — | — | — |
Q1 2025 | Feb 9, 2025 | — | $-0.03 | — | — |
Q2 2024 | May 29, 2024 | — | — | — | — |
Q2 2024 | May 21, 2024 | — | $-0.01 | — | — |
Q1 2024 | Feb 26, 2024 | — | — | — | — |
Q3 2023 | Sep 28, 2023 | — | $0.11 | — | — |
Q2 2023 | May 31, 2023 | — | — | — | — |
Q2 2023 | May 26, 2023 | — | $-0.06 | — | — |
Q2 2023 | Apr 28, 2023 | — | — | — | — |
Q2 2022 | May 31, 2022 | — | — | — | — |
Q1 2022 | Feb 28, 2022 | — | $-0.07 | — | — |
Q4 2021 | Nov 2, 2021 | — | $-0.03 | — | — |
Q1 2021 | Feb 15, 2021 | — | $-0.04 | — | — |
Q4 2020 | Oct 30, 2020 | — | $-0.04 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.03 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.03 | — | — |
Q1 2020 | Feb 12, 2020 | — | $-0.09 | — | — |
Q4 2019 | Oct 31, 2019 | — | $-0.07 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.03 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ONC.L
What is ONC.L's current stock price?
Oncimmune Holdings plc (ONC.L) is currently trading at $1.14 per share. The stock has moved -4.20% today.
What is the analyst price target for ONC.L?
No analyst price targets are currently available for this stock.
What sector is Oncimmune Holdings plc in?
Oncimmune Holdings plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the LSE exchange.
What is ONC.L's market cap?
Oncimmune Holdings plc has a market capitalization of $0.00 billion, making it a small-cap company.
Does ONC.L pay dividends?
No, Oncimmune Holdings plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorDEST.L
Destiny Pharma plc
$3.00
Mkt Cap: $0.3B
DVRG.L
DeepVerge plc
$0.15
Mkt Cap: $0.1B
HELD.L
Hellenic Dynamics Plc
$0.95
Mkt Cap: $0.1B
KNB.L
Kanabo Group Plc
$0.23
Mkt Cap: $0.1B
LLAI.L
LungLife AI, Inc.
$4.15
Mkt Cap: $0.1B
LLA.L
LungLife AI, Inc.
$5.00
Mkt Cap: $0.1B
OCTP.L
Oxford Cannabinoid Technologies Holdings Plc
$0.12
Mkt Cap: $0.1B
OVB.L
Ovoca Bio plc
$1.15
Mkt Cap: $0.1B
RENE.L
ReNeuron Group plc
$3.38
Mkt Cap: $0.2B
TLY.L
Totally plc
$0.24
Mkt Cap: $0.0B
Explore stocks similar to ONC.L for comparison